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S U M M A R Y
Background: Clostridium difﬁcile infection (CDI) is a common cause of nosocomial diarrhoea. People in the
general community are not usually considered to be at risk of CDI. CDI is associated with a high risk of
morbidity and mortality. The risk of severity is deﬁned by the Clostridium Severity Index (CSI).
Methods: The cases of 136 adult patients with CDI treated at the University Hospital of Tours, France
between 2008 and 2012 are described. This was a retrospective study.
Results: Among the 136 patients included, 62 were men and 74 were women. Their median age was
64.4 years (range 18–97 years). Twenty-six of the 136 (19%) cases were community-acquired (CA) and
110 (81%) were healthcare-acquired (HCA). The major risk factors for both groups were long-term
treatment with proton pump inhibitors (54% of CA, 53% of HCA patients) and antibiotic treatment within
the 2.5 months preceding the CDI (50% of CA, 91% of HCA). The CSI was higher in the CA-CDI group (1.56)
than in the HCA-CDI group (1.39). Intensive care was required for 8% of CA-CDI and 16.5% of HCA-CDI
patients.
Conclusions: CDI can cause community-acquired diarrhoea, and CA-CDI may be more severe than HCA-
CDI. Prospective studies of CDI involving people from the general community without risk factors are
required to conﬁrm this observation.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Clostridium difﬁcile is an anaerobic, Gram-positive, spore-
forming bacillus. These bacteria are found throughout the
environment, are a widespread problem in healthcare settings,
and cause healthcare-acquired C. difﬁcile infection (HCA-CDI).
C. difﬁcile spores are resistant to gastric acid: following ingestion,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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intestine and colonize the lower intestinal tract. Disturbance of the
host’s microbiota favours the multiplication of C. difﬁcile, leading to
colonization, which in itself may become clinically symptomatic.
The biggest risk factor for colonization by C. difﬁcile is antibiotic
exposure within the 2.5 months preceding the CDI.1 Comorbidities
favouring this infection include immunosuppression, diabetes,
chronic renal failure, and recurring urinary tract infection. Chronic
exposure to proton pump inhibitors (PPIs) is also a risk factor.2–4
CDI is associated with a high risk of morbidity and mortality.
Symptoms range from mild diarrhoea to severe pseudomembra-
nous colitis with associated toxic megacolon, colonic perforation,
and multiple organ failure.5 Four risk factors for the severe form
of CDI are used to calculate the Clostridium Severity Index (CSI)
score to estimate the risk of severe disease: history of immuno-
suppression, hyperleukocytosis >20  109 cells/l, acute renal
injury, and an albumin concentration <30 g/l.6
The risk of CDI in the overall population is generally considered
to be low. However, recent reports have shown that the incidence
of this infection is continuing to rise among patients with no
known risk factors because of changes in the community
environment that have favoured the emergence of these bacteria
in the general population.7,8 In addition, antibiotics and PPI drugs
are prescribed increasingly and in large quantities in the outpatient
healthcare setting, and these drugs favour community-acquired C.
difﬁcile infection (CA-CDI).3 As a result, C. difﬁcile has started to
spread to the general population. One study in the USA found no
association between CA-CDI and food or animal exposure.9
However, other sources of C. difﬁcile contamination may exist
for people in the general population.
Most studies on CA-CDI have been carried out in the USA,
Sweden, and the UK (Table 3). Few studies on CA-CDI have been
performed in France; however risk factors such as the misuse of
antibiotics10 and PPIs constitute a real public health problem in the
French population.
The purpose of this study was to examine the epidemiology of
CA-CDI in hospitalized patients in the University Hospital Centre of
Tours, France between 2008 and 2012. The clinical and biological
proﬁle of CA-CDI and the health outcomes of these patients are
described.
2. Materials and methods
2.1. Study design and population
This retrospective observational analysis was performed at the
University Hospital of Tours, France.
Adult patients hospitalized between January 2008 and Decem-
ber 2012 who tested positive for the Clostridium difﬁcile toxin were
included.
2.2. Bacteriological diagnosis
The diagnosis was conﬁrmed by microbiological testing: before
July 2012, ImmunoCard Toxins A&B (Meridian Bioscience) was
used; after July 2012, C. difﬁcile Quick Check Complete (Alere)
was used. Throughout the study period, a toxigenic culture was
performed if the C. difﬁcile toxin test was negative.
2.3. Data collection
Patient medical history was obtained from the electronic
medical records. Laboratory tests and imaging tests were performed
on the day of diagnosis. Variables such as sex, age, lifestyle, and
diagnosis on hospital admission were collected. The following
known risk factors for CDI were recorded: immunosuppression dueto cancer, chronic corticoid therapy, dialysis, diabetes, recurrent
urinary infection, antibiotic therapy less than 2.5 months before the
CDI, chronic PPI therapy, history of abdominal or stomach surgery,
chronic inﬂammatory diarrhoea, and history of CDI. The medical
reason for the use of antibiotics within the 2.5 months before the
CDI and the family of antibiotic used were also recorded.
2.4. The Clostridium Severity Index (CSI)
Following the conﬁrmation of diagnosis with a positive toxin
assay, the CSI score was calculated (on the same day) by analyzing
four severity risk factors: history of immunosuppression, white
blood cell count at admission >20  109/l, blood albumin
concentration <30 g/l, and acute renal injury (MDRD (Modiﬁcation
of Diet in Renal Disease) <60 ml/min or creatinine >1.5 times the
baseline value). Each factor is awarded 1 point, which leads to a
score of 0 to 4. The CSI predicts the severity of the CDI. According to
the analysis of Lungulescu et al.,6 patients with a high score are
more likely to have a severe infection than those with a low score.
The speciﬁcity of this index increases with each point: 0 = 0%,
1 = 23%, 2 = 65%, 3 = 92%, and 4 = 95%.
2.5. Deﬁnitions
Severe complications of CDI were deﬁned as follows: severe
dehydration with electrolyte disorders, acute renal injury due to
dehydration, intestinal perforation, peritonitis, toxic megacolon,
and death.5
All patients who tested positive for Clostridium toxin in the ﬁrst
48 h following hospitalization were deﬁned as having CA-CDI (on
the condition that the patient had not previously stayed overnight
in a healthcare setting within the past 3 months).
The outcome of CDI was deﬁned as favourable if diarrhoea
subsided within 6 days of antibiotic therapy. Death, refractory CDI,
and recurrent CDI were considered to be poor outcomes. Refractory
CDI was deﬁned as persistent diarrhoea after 6 days of treatment.
Recurrent infection was deﬁned as a new episode of diarrhoea
commencing at 2 days after successful treatment of the primary
episode.11,12
2.6. Statistical analysis
A univariate analysis was conducted for the risk factors of CDI
and the clinical and biological proﬁles of CA-CDI and HCA-CDI
patients. The CSI score was used to classify the risk of severity as
low (a CSI score 1), or high (a CSI score 2). The Chi-square test
was used to compare categorical variables. A p-value of <0.05
was considered statistically signiﬁcant. Multivariate analysis was
conducted for the four variables used to calculate the CSI score
(risk factors) in order to determine whether these factors affected
the course of the disease. The outcome was a binary variable,
therefore logistic regression was used (see Appendix 1).
3. Results
3.1. Patient demographics
Over the 5-year study period, 140 patients with diarrhoea
tested positive for C. difﬁcile toxins. However, it was not possible to
determine whether the CDI was HCA-CDI or CA-CDI in four cases;
therefore, only 136 patients (62 men and 74 women) were
included in this study. Twenty-six of the 136 (19%) cases were CA
and 110 (81%) cases were HCA. Only 48% (65/136) of the patients
were aged >65 years. The mean age was 64.4 years. The mean age
of patients with CA-CDI was 63.2 years and that of patients with
HCA-CDI was 64.7 years. Infectious diseases were the main reason
Table 1
Patient risk factors for CDIi
CDI risk factors (number of patients) CAii-CDI (n = 26) HCAiii-CDI (n = 110) p-Value
Immunosuppression (n = 65) 35% (9/26) 52% (57/110) 0.15
Diabetes (n = 35) 8% (2/26) 28% (33/110) 0.02
Chronic renal disease (n = 38) 23% (6/26) 28% (33/110) 0.48
Recurrent urinary infection (n = 10) 8% (2/26) 79% (8/110) 0.93
Age >65 years (n = 65) 46% (12/26) 48% (53/110) 0.82
Hospitalization within 12 weeks (n = 110) 0% (0/26) 100% (110/110) <0.01
History of abdominal or stomach surgery (n = 36) 21% (5/26) 28% (31/109) 0.45
Proton pump inhibitors (n = 72) 54% (14/26) 53% (58/110) 0.77
Antibiotic therapy <2.5 months (n = 114) 50% (13/26) 91% (100/110) <0.01
CDIi: Clostridium difﬁcile infection; CAii :Community-acquired; HCAiii : Healthcare-acquired.
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emergency unit because of diarrhoea was 19% (26/136).
3.2. Risk factors for CDI (Table 1)
Risk factors were found for 134 patients; two patients (1%)
had no recorded risk factors for CDI. Risk factors were the
following: 80% (110/136) of patients had been hospitalized
within the last 3 months, 48% (65/136) were immunosuppressed
(due to cancer, long-term steroid therapy, or dialysis), 26% (36/
136) had a history of abdominal surgery, 84% (114/136) had
received antibiotics within the 2.5 months preceding the CDI, and
53% (72/136) were receiving long-term PPI therapy. The long-
term use of PPIs was a risk factor for 54% of CA-CDI patients (14/
26) and 53% of HCA-CDI patients (58/110). Antibiotic use was
a risk factor for 50% of CA-CDI patients (13/26) and 91% of
HCA-CDI patients (100/110).
Antibiotic therapy preceding the CDI had been prescribed to
treat lower respiratory tract infection (n = 46), sepsis (n = 35), or
urinary tract infection (n = 31). Beta-lactams were the most
frequently prescribed antibiotics (n = 105), accounting for 84.6%
of CA and 93% of HCA patients who had received antibiotics. Other
antibiotics prescribed included ﬂuoroquinolones (n = 34), amino-
glycosides (n = 31), and macrolides (n = 14). In most cases (n = 77),
the patient had received more than one antibiotic during the
2.5 months preceding the CDI. Twenty patients had received four
or more drugs.Table 2
Severity of infection in the two study groups: CA-CDI and HCA-CDI
Variables (number of patients) 
Risk of severity – CSIiv score
on the day of diagnosis
1 (n = 76) 
2 (n = 60) 
Average CSI score 
WBCv >20  109 cells/l (n = 16) 
Hypoalbuminemia <30 g/l (n = 66) 
Acute renal failure (MDRDvi <60 ml/min or
creatinine >1.5 times the baseline value)
(n = 50)
Immunodepression (n = 66) 
Severe complications
(n = 29)
Required ICUvii management (n = 2) 
Toxic megacolon (n = 2) 
Rectorrhagia (n = 5) 
Death (n = 20) 
Outcome unfavourable
(n = 33)
Refractory (n = 17) 
Recurrent (n = 16) 
CAi : Community-acquired; CDIii : Clostridium difﬁcile infection HCAiiiHealthcare-acquired
Diet in Renal Disease; ICUvii : Intensive care unit.3.3. Severity of infection (Table 2)
Most patients (114/136) had at least one risk factor for
severe infection (CSI score 1). Hyperleukocytosis and acute
renal injury were more prevalent in the CA-CDI group than in
the HCA-CDI group. However, immunosuppression was more
frequent in the HCA-CDI group than in the CA-CDI group. The
average CSI score was higher in the CA-CDI group (1.56) than in
the HCA-CDI group (1.39). The proportion of patients with a CSI
score 2 was signiﬁcantly smaller in the HCA-CDI group than in
the CA-CDI group (Figure 1). Similarly, the proportion of patients
with a CSI score 1 was signiﬁcantly larger in the HCA-CDI
group than in the CA-CDI group. Overall, 15% (21/136) of all
patients (8% in the CA-CDI group and 16.5% in the HCA-CDI
group) had severe CDI requiring intensive care. The difference
between the two groups was not signiﬁcant (p > 0.05). Four
patients experienced rectorrhagia (3%, 4/136) and two patients
had toxic megacolon (1.5%, 2/136). Twenty patients died: 8%
(2/26) of the CA-CDI group and 16% (18/110) of the HCA-CDI
group.
3.4. C. difﬁcile treatment
A total of 111 (82%) patients were treated with metronidazole
alone, nine patients (7%) with vancomycin alone, and ﬁve patients
(4%) with both antibiotics in combination.CAi-CDIii (n = 26) HCAiii-CDI (n = 110) p-Value
38% (10/26) 60% (66/110) 0.047
54% (16/26) 42% (44/110) 0.047
1.56 1.39 -
23% (6/26) 9% (10/110) 0.047
38% (10/26) 50% (56/110) 0.253
54% (14/26) 33% (36/110) 0.045
35% (9/26) 52% (57/110) 0.114
36% (9/26) 11% (12/110 0.003
0% (0/26) 2% (2/110) 0.489
4% (1/26) 3% (4/110) 0.959
8% (2/26) 16% (18/110) 0.262
8% (2/26) 14% (15/110) 0.492
8% (2/26) 13% (14/110) 0.492
; CSIiv:Clostridium Severity Index; WBCv: White blood cells; MDRDvi :Modiﬁcation of
Figure 1. CAi-CDIii (n = 26).....HCAiii- CDI (n = 110)..... Risk of severity - CSIiv score at
diagnosis day CAi: Community-acquired, CDIii :Clostridium difﬁcile infection HCAiii :
Health care acquired Clostridium difﬁcile infection CSIiv : Clostridium severity index.
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CDI was treated successfully in 76% (103/136) of cases. Thirty-
three (24%) patients had either refractory (n = 17) or recurrent
disease (n = 16) (Table 2). An unfavourable outcome occurred more
frequently in the HCA-CDI group (26%; 29/110) than in the CA-CDI
group (15%; 4/26). The recurrence rate was slightly higher in the
HCA-CDI group (13%; 14/110) than in the CA-CDI group (8%; 2/26).
Risk factors for an unfavourable outcome were the following: a
blood albumin concentration <30 g/l and acute renal injury
(MDRD <60 ml/min or creatinine >1.5 times the baseline value).
Hyperleukocytosis >20  109 cells/l also had a negative effect on
the course of disease, however this was not signiﬁcant (p = 0.943)
(see Appendix 1).Table 3
Literature review
Year of the study;
author
Type of study Country CA-CDIi/total CDI
(%)
CAii-CDI/
total CDI
(n)
1983–1984;
Riley et al.15
Prospective Australia NAvi 89 
1994;
Hirschhorn et al.16
Retrospective USA NA 51 
1995;
Karlstrom et al.20
Prospective Sweden 28% 1437/5133 
1995;
Kyne et al.21
Prospective Ireland 11% 8/73 
1994–2004;
Dial et al.3
Prospective UK NA 1233 
1999–2000;
Beaugerie et al.22
Prospective France NA 4 
2004–2007;
Kuntz et al.7
Prospective USA 44% 304/684 
2005–2006;
Kutty et al.14
Prospective USA 20% 212/1046 
2009–2010;
Lessa8
Prospective USA 32% 3269/10342
2008;
Dumyati et al.9
Retrospective USA 18% 67/366 
2009–2011 ;
Chitnis et al.4
Prospective USA NA 984 
2008 ;
Wilcox et al.23
Prospective UK 2.1% 42/2000 
2008;
Bauer et al.24
Prospective Netherlands 1.5% 37/2423 
2014;
Clohessy et al.17
Retrospective Australia 29% 38/129 
CDIi:Clostridium difﬁcile infection; CAiiCommunity-acquired; ATBiii Antibiotics; PPIiv
Nonsteroidal anti-inﬂammatory drugs; GERDvii Gastroesophageal reﬂux disease; NAviii4. Discussion
Among the 136 cases, nearly 20% of the CDI were considered to
be community-acquired, and 8% (2/26) of these patients had no
risk factor for CDI.
This study conﬁrms that the use of antibiotics within the
2.5 months preceding C. difﬁcile infection is a major risk factor for
CDI, especially for HCA-CDI. The chronic use of PPIs was identiﬁed
as a major risk factor for CA-CDI. PPIs were a risk factor in 54% (14/
26) of CA cases and antibiotic therapy was a risk factor in 50% (13/
26) of cases. Six patients received both PPIs and antibiotics. Among
those with CA-CDI, patients received PPIs without antibiotics in
31% of cases (8/26) and antibiotics without PPIs in 23% of cases (6/
26). Only 19% (5/26) of CA-CDI patients received neither antibiotics
nor PPIs before CDI. Hence, the use of PPIs was the main risk factor
for CA-CDI. PPIs modify intestinal pH; nevertheless the origin of
the association between PPI and CDI remains unclear (Nerandzic
et al.13). Therefore, as with antibiotics, PPIs may also disturb
the intestinal microbiota, which favours the emergence of C.
difﬁcile. These observations are consistent with those of Dial et al.,3
who also found that the long-term use of PPIs is a major risk factor
for CA-CDI. Furthermore, the authors noted a decline in the
prescription of antibiotics and an increase in the prescription of
PPIs. Hence, PPIs may soon surpass antibiotics as the main risk
factor for CA-CDI. On the other hand, a study carried out by Kutty
et al. in North Carolina did not identify PPIs as a risk factor for
CA-CDI.14
Since the ﬁrst description of CA-CDI 30 years ago,15,16 research
teams across the world have been trying to understand this
disease, and in particular to identify risk factors that could help to
explain its occurrence. There are many discrepancies in the
ﬁndings reported (Table 3). Some have described the overuse ofRisk factors for CA-CDI
ATBiii within
2.5 months preceding
CA-CDI
Chronic PPIiv H2RAv Other
- - - -
Yes - - -
Yes - - Inﬂammatory bowel disease
Yes - - -
Yes Yes Yes NSAIDS, renal failure,
inﬂammatory bowel disease
Yes - - -
Yes Yes Yes -
Yes - - GERD, cardiac failure
 NA NA NA NA
Yes Yes No -
Yes Yes - Contact with children
younger than 1 year
Yes No No -
Yes Yes Yes -
Yes Yes - -
Proton pumps inhibitor; H2RAv Histamine H2 receptor antagonists; NSAIDSvi
Not applicable.
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that both antibiotics and chronic treatment with PPIs are risk
factors. It is concluded that physicians in hospitals, but also general
practitioners, should be more cautious in the prescription of
antibiotics and PPIs to prevent patients from developing CDI.
Five patients with CA-CDI did not have any known risk factors.
These patients may have been asymptomatic carriers before they
became ill. The origin of Clostridium infection in these patients is
unknown. The most probable source is exposure to spores by
contact with animals, people, or contaminating environments. The
environmental reservoir of this bacterium needs to be better
explored if we want to stop the dissemination of CA-CDI. Chitnis
et al.4 investigated food and exposure to animals as sources of C.
difﬁcile for community patients, but their ﬁndings were negative.
However, they observed that the community patients who had
received very little or no outpatient care had frequently been
exposed to infants less than 1 year old. A similar study by Dumyati
et al.9 was also unable to identify the source of CA-CDI. The present
study was retrospective. Therefore, it was not possible to explore
the source of CA-CDI or to identify the speciﬁc clones involved by
molecular typing.
There are at least two explanations for the CDI in the patients
without identiﬁable risk factors in the present study: (1) the
patient had a risk factor for CDI (such as an illness) that could not
be identiﬁed because of the retrospective nature of the study, or (2)
the patient was susceptible to CDI because of some as yet
unidentiﬁed risk factor. The role of healthy carriers in the
dissemination of C. difﬁcile spores and bacteria in the community
setting may be underestimated. Appropriate prospective studies
are needed to explore these possibilities.
CA-CDI patients were found to be more likely to develop a
severe infection than HCA-CDI patients. Indeed, 54% of patients
in the CA-CDI group but only 42% of those in the HCA-CDI group
had a CSI score 2. A signiﬁcantly higher proportion of patients in
the CA-CDI group than in the HCA-CDI group required intensive
care unit management (36% vs. 11%, respectively). By contrast,
Clohessy et al. did not ﬁnd any differences between CA-CDI
and HCA-CDI in terms of severity and outcome in Australian
patients.17 Nevertheless, the present study did not explore
patients with CA-CDI who were treated outside of a hospital
setting.
Interestingly, although CA-CDI seemed to be more severe in the
beginning, the rate of favourable outcome in this group was higher
than that in the HCA-CDI group (85% vs. 74%, respectively). These
ﬁndings are consistent with an American study by Lessa et al.,18
which showed that the recurrence rate was higher in healthcare-
associated than in community cases.
The proportion of immunosuppressed patients was higher in
the HCA-CDI group than in the CA-CDI group. This is not surprising,
given that hospitalized patients are highly exposed to and
dependent on medical care. Immunosuppression also explains
the low white blood cell counts in the HCA-CDI group. Neverthe-
less, the proportion of patients with hyperleukocytosis and acute
renal injury was higher in the CA-CDI group than in the HCA-CDI
group. CDI may have been more severe in community patients than
in nosocomial patients because: (1) community patients may have
been more sensitive to C. difﬁcile because of as yet unidentiﬁed
risk factors, or (2) bacterial strains encountered in the general
community may be more virulent than hospital-based strains.
In addition, the medical management of CDIs may be delayed
in community patients. Indeed, CDI is still considered to be a
hospital-acquired infection, therefore it is not standard practice to
screen for C. difﬁcile in outpatient departments, even for
individuals presenting with diarrhoea and fever. Generally, other
tests are performed ﬁrst. Thus, community patients may be
diagnosed at a late and more severe stage of infection.Alternatively, infection by very virulent strains may explain the
severity of the diarrhoea and inﬂammation in CA-CDI patients.
Unfortunately, it was not possible to perform PCR ribotyping on the
isolates and thus it is not known whether the patients in the
present study were infected with particular ribotypes such as 078,
which has previously been associated with CA-CDI (Rodrı´guez-
Pardo et al.).19 Further studies are needed to characterize the
bacterial strains involved in CA-CDI and HCA-CDI cases and the
changes occurring to the microbiota of CDI patients.
In conclusion, CA-CDI is an increasingly frequent occurrence
in the French population. It is a real problem from both an
epidemiological and an economic perspective. This increase in the
incidence of CDI places a major burden on healthcare budgets and
will necessitate a change in future management.
The careful monitoring of the prescription of antibiotics and
PPIs would help to reduce the incidence of CA-CDI. This is
especially true for the prescription of beta-lactam antibiotics. In
this study, there were too few cases of CA-CDI to compare all
variables between the community-acquired and nosocomial cases.
A prospective study of CA-CDI is thus required to conﬁrm our
observations, in particular the ﬁnding that CDI is more severe in
community patients than in nosocomial patients.
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Appendix A
To analyze further the results shown in Table 2, a multivariate
analysis was performed of the variables that had the largest effect
on the outcome of the patients. Outcome is a binary variable,
therefore logistic regression was used (‘logit’ model). Four major
explanatory variables were tested in this model: acute renal
failure, history of immunosuppression, albumin level <30 g/l, and
hyperleukocytosis (>20 T 109 cells/l).
Tests verifying the signiﬁcance of the model rejected the null
hypothesis at 99%. The choice of variables in our model is therefore
relevant (Supplementary Material, data 1).
In theory, the four variables selected should have a negative
value (and thus a lower odds ratio than 1) because they should
negatively affect the chances of a favourable outcome (Supple-
mentary Material, data 2). This was the case for the two variables
found to be signiﬁcant at the threshold of 5%: acute renal failure
(p = 0.020) and serum albumin <30 g/l (p = 0.016). Hyperleuko-
cytosis >20  109 cells/l was estimated to have a negative effect
on outcome, but this result was not signiﬁcant (p = 0.412). A
history of immunosuppression did not affect the course of the
disease (p = 0.943).
The model was then expanded to only nosocomial patients and
community patients. Unfortunately, due to the low number of
community patients, neither the signiﬁcance of the model nor the
signiﬁcance of variables was satisfactory, even at the threshold
of 10%. Thus, the results obtained for nosocomial patients are
similar to those obtained for the model including all patients.
Appendix B. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2015.06.007.
M. Ogielska et al. / International Journal of Infectious Diseases 37 (2015) 36–41 41References
1. Kyne I, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality
associated with nosocomial diarrhoea due to Clostridium difﬁcile. Clin Infect Dis
2002;34:346–53.
2. Bishara J, Farah R, Mograbi J, Khalaila W, Abu-Elheja O, Mahamid M, et al.
Obesity as risk factor for Clostridium difﬁcile infection. Clin Infect Dis
2013;57:489–93.
3. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents
and risk of community-acquired Clostridium difﬁcile-associated disease. JAMA
2005;294:2989–95.
4. Chitnis AS, Holzbauer SM, Belﬂower RM, Winston LG, Bamberg WM, Lyons C,
et al. Epidemiology of community-associated Clostridium difﬁcile infection,
2009 thought 2011. JAMA Intern Med 2013;173:1359–67.
5. Pant CH, Sferra TJ, Deshpande A, Minocha A. Clinical approach to severe
Clostridium difﬁcile infection: update for the hospital practitioner. Eur J Intern
Med 2011;22:561–8.
6. Lungulescu OA, Cao W, Gatskevich E, Tlhabano L, Stratidis JG. CSI: A severity
index for Clostridium difﬁcile infection at the time of admission. J Hosp Infect
2011;79:151–4.
7. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of
and risk factors for community-associated Clostridium difﬁcile infection: a
nested case–control study. BMC Infect Dis 2011;11:194.
8. Lessa FC. Community-associated Clostridium difﬁcile infection: how real is it?
Anaerobe 2013;24:121–3.
9. Dumyati G, Stevens V, Hannett GE, Thompson AD, Long C, MacCannell D, et al.
Community-associated Clostridium difﬁcile infections, Monroe County, New
York, USA. Emerg Infect Dis 2012;18:392–400.
10. Goossen H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in
Europe and association with resistance: a cross-national database study. Lancet
2005;365:579–87.
11. Arora V, Kachroo S, Ghantoji SS, DuPont HL, Garey KW. High Horn’s index score
predicts poor outcomes in patients with Clostridium difﬁcile infection. J Hosp
Infect 2011;79:23–6.
12. Eyre DW, Walker AS, Wyllie D, Dingle KE, Grifﬁths D, Finney J, et al. Predictors
of ﬁrst recurrence of Clostridium difﬁcile infection: implication for initial man-
agement. Clin Infect Dis 2012;55(Suppl 2):S77–87.13. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to
explain the association between proton pump inhibitors and Clostridium difﬁcile
infection. Antimicrob Agents Chemother 2009;53:4133–7.
14. Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Joyce F, et al. Risk Factors
for and estimated incidence of community-associated Clostridium difﬁcile in-
fection, North Carolina, USA. Emerg Infect Dis 2010;16:197–204.
15. Riley TV, Wymer V, Bamford VW, Bowman RA. Clostridium difﬁcile in general
practice and community health. J Hyg (Lond) 1986;96:13–7.
16. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of
community-acquired Clostridium difﬁcile associated diarrhea. J Infect Dis
1994;169:127–33.
17. Clohessy P, Merif J, Post JJ. Severity and frequency of community-onset Clos-
tridium difﬁcile infection on an Australian tertiary hospital campus. Int J Infect
Dis 2014;29:152–5.
18. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden
of Clostridium difﬁcile infection in the United States. N Engl J Med 2015;372:
825–34.
19. Rodrı´guez-Pardo D, Almirante B, Bartolome´ RM, Pomar V, Mirelis B, Navarro
F, et al. Barcelona Clostridium difﬁcile Study Group. Epidemiology of Clostrid-
ium difﬁcile infection and risk factors for unfavorable clinical outcomes:
results of a hospital-based study in Barcelona, Spain. J Clin Microbiol
2013;51:1465–73.
20. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study
of Clostridium difﬁcile-associated diarrhea in Sweden. The Swedish C. difﬁcile
Study Group. Clin Infect Dis 1998;26:141–5.
21. Kyne L, Merry C, O’Connell B, Keane C, O’Neill D. Community-acquired Clostrid-
ium difﬁcile infection. J Infect 1998;36:287–8.
22. Beaugerie L, Flahault A, Barbut F, Atlans P, Lalande V, Cousin P, et al. Antibiotic-
associated diarrhoea and Clostridium difﬁcile in the community. Aliment Phar-
macol Ther 2003;17:905–12.
23. Wilcox MH, Mooney L, Bendall R, Settle CD, Fawley WN. A case–control study of
community-associated Clostridium difﬁcile infection. J Antimicrob Chemother
2008;62:388–96.
24. Bauer MP, Veenendaal D, Verhoef L, Bloembergen P, Van Dissel JT, Kuijper EJ.
Clinical and microbiological characteristics of community-onset Clostridi-
um difﬁcile infection in the Netherlands. Clin Microbiol Infect 2009;15:
1087–92.
